{"id":"somavert","rwe":[{"pmid":"30000555","year":"2006","title":"Pegvisomant.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"36276070","year":"2022","title":"Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma.","finding":"","journal":"Frontiers in oncology","studyType":"Clinical Study"},{"pmid":"35994522","year":"2022","title":"Moving Protein PEGylation from an Art to a Data Science.","finding":"","journal":"Bioconjugate chemistry","studyType":"Clinical Study"},{"pmid":"29805678","year":"2018","title":"Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol.","finding":"","journal":"Oncology letters","studyType":"Clinical Study"}],"tags":[{"label":"Growth Hormone Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Growth hormone receptor","category":"target"},{"label":"GHR","category":"gene"},{"label":"H01AX01","category":"atc"},{"label":"Active","category":"status"},{"label":"Acromegaly","category":"indication"},{"label":"Pharmacia And Upjohn","category":"company"},{"label":"Approved 2000s","category":"decade"}],"phase":"marketed","safety":{"safetySignals":[{"llr":1432.003,"date":"","count":236,"signal":"Insulin-like growth factor increased","source":"DrugCentral FAERS","actionTaken":"Reported 236 times (LLR=1432)"},{"llr":381.217,"date":"","count":67,"signal":"Blood growth hormone increased","source":"DrugCentral FAERS","actionTaken":"Reported 67 times (LLR=381)"},{"llr":279.147,"date":"","count":92,"signal":"Needle issue","source":"DrugCentral FAERS","actionTaken":"Reported 92 times (LLR=279)"},{"llr":183.809,"date":"","count":24,"signal":"Insulin-like growth factor abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=184)"},{"llr":148.62,"date":"","count":34,"signal":"Pituitary tumour","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=149)"},{"llr":147.373,"date":"","count":31,"signal":"Lipohypertrophy","source":"DrugCentral FAERS","actionTaken":"Reported 31 times (LLR=147)"},{"llr":133.013,"date":"","count":35,"signal":"Pituitary tumour benign","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=133)"},{"llr":131.22,"date":"","count":72,"signal":"Injection site bruising","source":"DrugCentral FAERS","actionTaken":"Reported 72 times (LLR=131)"},{"llr":131.064,"date":"","count":115,"signal":"Injection site pain","source":"DrugCentral FAERS","actionTaken":"Reported 115 times (LLR=131)"},{"llr":128.878,"date":"","count":162,"signal":"Product dose omission issue","source":"DrugCentral FAERS","actionTaken":"Reported 162 times (LLR=129)"},{"llr":128.783,"date":"","count":26,"signal":"Insulin-like growth factor decreased","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=129)"},{"llr":117.268,"date":"","count":18,"signal":"Injection site hypertrophy","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=117)"},{"llr":111.899,"date":"","count":52,"signal":"Injection site mass","source":"DrugCentral FAERS","actionTaken":"Reported 52 times (LLR=112)"},{"llr":102.58,"date":"","count":27,"signal":"Rectal polyp","source":"DrugCentral FAERS","actionTaken":"Reported 27 times (LLR=103)"},{"llr":99.138,"date":"","count":33,"signal":"Injection site discomfort","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=99)"}],"commonSideEffects":[{"effect":"Infection","drugRate":"23%","severity":"common","organSystem":""},{"effect":"Pain","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Flu syndrome","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Abnormal liver function tests","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Injection site reaction","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Accidental injury","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Back pain","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Sinusitis","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Chest pain","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Paresthesia","drugRate":"7%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Marked transaminase elevations","drugRate":"0.8%","severity":"serious"},{"effect":"Anaphylactic reactions","drugRate":"","severity":"serious"},{"effect":"Laryngospasm","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Systemic hypersensitivity reactions","drugRate":"","severity":"serious"},{"effect":"Lipohypertrophy at injection sites","drugRate":"","severity":"serious"},{"effect":"Substantial weight gain","drugRate":"","severity":"serious"},{"effect":"Chronic hepatitis","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=somavert","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:52:01.629181+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Somavert","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:52:08.628269+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:52:07.162818+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:52:01.701342+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=somavert","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:52:07.484569+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Growth hormone receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:52:08.628203+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201515/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:52:08.201013+00:00"}},"allNames":"trovert","offLabel":[],"synonyms":["B-2036 PEG","pegvisomant","somavert","pegvisomant (genetical recombination)","B2036-PEG","trovert"],"timeline":[{"date":"2002-11-13","type":"positive","source":"DrugCentral","milestone":"EMA approval"},{"date":"2003-03-25","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pharmacia And Upjohn)"}],"brandName":"Trovert","ecosystem":[{"indication":"Acromegaly","otherDrugs":[{"name":"bromocriptine","slug":"bromocriptine","company":"Us Pharms Holdings I"},{"name":"lanreotide","slug":"lanreotide","company":"Ipsen Pharma"},{"name":"octreotide","slug":"octreotide","company":"Novartis"}],"globalPrevalence":1100000}],"mechanism":{"target":"Growth hormone receptor","novelty":"Follow-on","targets":[{"gene":"GHR","source":"DrugCentral","target":"Growth hormone receptor","protein":"Growth hormone receptor"}],"moaClass":"Growth Hormone Receptor Antagonists","modality":"Small Molecule","drugClass":"Growth Hormone Receptor Antagonist","explanation":"","oneSentence":"","technicalDetail":"Somavert is a pegylated growth hormone receptor antagonist that binds to the extracellular domain of the growth hormone receptor, preventing the binding of growth hormone and subsequent activation of the JAK/STAT signaling pathway."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Pegvisomant","title":"Pegvisomant","extract":"Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. It is delivered as a powder that is mixed with water and injected under the skin."},"commercial":{"launchDate":"2003","_launchSource":"DrugCentral (FDA 2003-03-25, PHARMACIA AND UPJOHN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5015","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=somavert","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=somavert","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Pegvisomant","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:34:01.469830","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:09.914644+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"lonapegsomatropin","drugSlug":"lonapegsomatropin","fdaApproval":"2021-08-25","relationship":"same-target"},{"drugName":"somapacitan","drugSlug":"somapacitan","fdaApproval":"2020-08-28","relationship":"same-target"},{"drugName":"somatrem","drugSlug":"somatrem","fdaApproval":"1985-10-17","relationship":"same-target"},{"drugName":"somatrogon","drugSlug":"somatrogon","fdaApproval":"2023-06-27","relationship":"same-target"},{"drugName":"somatropin","drugSlug":"somatropin","fdaApproval":"1976-07-30","relationship":"same-target"}],"genericName":"somavert","indications":{"approved":[{"name":"Acromegaly","source":"DrugCentral","snomedId":74107003,"regulator":"FDA","globalPrevalence":1100000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Eur J Endocrinol, 2021 (PMID:34061771)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"lonapegsomatropin","brandName":"lonapegsomatropin","genericName":"lonapegsomatropin","approvalYear":"2021","relationship":"same-target"},{"drugId":"somapacitan","brandName":"somapacitan","genericName":"somapacitan","approvalYear":"2020","relationship":"same-target"},{"drugId":"somatrem","brandName":"somatrem","genericName":"somatrem","approvalYear":"1985","relationship":"same-target"},{"drugId":"somatrogon","brandName":"somatrogon","genericName":"somatrogon","approvalYear":"2023","relationship":"same-target"},{"drugId":"somatropin","brandName":"somatropin","genericName":"somatropin","approvalYear":"1976","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05470504","phase":"PHASE2","title":"Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-01-23","conditions":["Insulin Receptor Mutation","Partial Lipodystrophy"],"enrollment":25,"completionDate":"2028-01-31"},{"nctId":"NCT03882034","phase":"PHASE3","title":"Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2019-10-21","conditions":["Pituitary Disease"],"enrollment":12,"completionDate":"2025-09-30"},{"nctId":"NCT07179926","phase":"","title":"Effects of Pasireotide Lar Therapy on Bone Metabolism","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-09-08","conditions":["Acromegaly Due to Pituitary Adenoma","Acromegaly"],"enrollment":120,"completionDate":"2028-06"},{"nctId":"NCT05131100","phase":"","title":"Korean Regulatory Post Marketing Surveillance for Somavert","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-07-13","conditions":["Acromegaly"],"enrollment":100,"completionDate":"2026-09-15"},{"nctId":"NCT05069324","phase":"","title":"PegvisOMant and the Immune SystEm (PROMISE)","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2020-07-29","conditions":["Acromegaly"],"enrollment":62,"completionDate":"2024-12-15"},{"nctId":"NCT06597383","phase":"","title":"The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2023-11-24","conditions":["Acromegaly"],"enrollment":100,"completionDate":"2024-11"},{"nctId":"NCT00658879","phase":"","title":"Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-08-07","conditions":["Acromegaly"],"enrollment":251,"completionDate":"2016-11-09"},{"nctId":"NCT04998500","phase":"NA","title":"Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2021-08-01","conditions":["Fibrosis"],"enrollment":10,"completionDate":"2023-12-31"},{"nctId":"NCT01538966","phase":"NA","title":"Acromegaly Combination Treatment Study","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-03-29","conditions":["Acromegaly"],"enrollment":76,"completionDate":"2022-05-20"},{"nctId":"NCT02152124","phase":"","title":"Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-06-01","conditions":["Acromegaly"],"enrollment":21,"completionDate":"2017-08-31"},{"nctId":"NCT00383708","phase":"PHASE3","title":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","status":"COMPLETED","sponsor":"Ipsen","startDate":"2006-10","conditions":["Acromegaly"],"enrollment":125,"completionDate":"2008-10"},{"nctId":"NCT02952885","phase":"PHASE3","title":"Strict IGF-1 Control in Acromegaly","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2017-07-27","conditions":["Acromegaly"],"enrollment":10,"completionDate":"2020-05-07"},{"nctId":"NCT03225040","phase":"","title":"Bone MicroArchitecture in Acromegaly","status":"COMPLETED","sponsor":"Columbia University","startDate":"2016-08-03","conditions":["Acromegaly","Osteoporosis Risk"],"enrollment":77,"completionDate":"2019-12-21"},{"nctId":"NCT02782221","phase":"NA","title":"Lipolytic Effects of GH in Human Subjects in Vivo","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-05-30","conditions":["Metabolic Diseases","Growth Hormone Treatment"],"enrollment":9,"completionDate":"2017-01-15"},{"nctId":"NCT01732406","phase":"","title":"Acromegaly Treatment Quality of Life Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-01","conditions":["Acromegaly"],"enrollment":126,"completionDate":"2016-12-19"},{"nctId":"NCT01701973","phase":"PHASE4","title":"Effect of DPP4 Inhibition on Growth Hormone Secretion","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2013-01","conditions":["Obesity"],"enrollment":44,"completionDate":"2017-05"},{"nctId":"NCT01261000","phase":"NA","title":"Tissue Biomarker for Pegvisomant Action","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2010-11","conditions":["Acromegaly"],"enrollment":8,"completionDate":"2013-12"},{"nctId":"NCT02023918","phase":"PHASE2","title":"Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-01","conditions":["Diabetes","Metabolic Syndrome","Insulin Resistance"],"enrollment":6,"completionDate":"2015-12"},{"nctId":"NCT00376064","phase":"PHASE4","title":"Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-03","conditions":["Acromegaly"],"enrollment":20,"completionDate":""},{"nctId":"NCT01278342","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":["Acromegaly"],"enrollment":70,"completionDate":"2009-11"},{"nctId":"NCT02500095","phase":"NA","title":"Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-07","conditions":["Healthy"],"enrollment":10,"completionDate":"2016-11"},{"nctId":"NCT02668172","phase":"PHASE4","title":"Pasireotide LAR and Pegvisomant Study in Acromegaly","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2015-08","conditions":["Acromegaly"],"enrollment":60,"completionDate":"2017-06"},{"nctId":"NCT00976508","phase":"PHASE1","title":"Figitumumab Combined With Pegvisomant For Advanced Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-11","conditions":["Colorectal Neoplasms","Lung Neoplasms","Breast Neoplasms","Prostatic Neoplasms","Sarcoma"],"enrollment":24,"completionDate":"2012-10"},{"nctId":"NCT01893866","phase":"PHASE1","title":"A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-08","conditions":["Healthy Volunteers"],"enrollment":17,"completionDate":"2013-10"},{"nctId":"NCT01804413","phase":"NA","title":"Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2011-03","conditions":["Adults Growth Hormone Deficiency."],"enrollment":10,"completionDate":"2013-12"},{"nctId":"NCT00652379","phase":"NA","title":"Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2008-06","conditions":["Acromegaly","Insulin Resistance","Impaired Glucose Tolerance"],"enrollment":18,"completionDate":"2011-05"},{"nctId":"NCT01181973","phase":"PHASE1","title":"Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-10","conditions":["Bioavailability"],"enrollment":14,"completionDate":"2011-01"},{"nctId":"NCT00552851","phase":"PHASE4","title":"Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant","status":"UNKNOWN","sponsor":"University of Wuerzburg","startDate":"2006-06","conditions":["Acromegaly","Heart Failure","Hypertrophy, Left Ventricular"],"enrollment":4,"completionDate":"2010-12"},{"nctId":"NCT00970463","phase":"","title":"Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly","status":"COMPLETED","sponsor":"Herlev Hospital","startDate":"2006-01","conditions":["Growth Hormone Deficiency","Cardiac Function"],"enrollment":22,"completionDate":"2009-05"},{"nctId":"NCT00858143","phase":"","title":"Non Interventional Study For Patients Treated With Somavert®","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-01","conditions":["Acromegaly"],"enrollment":311,"completionDate":"2008-01"},{"nctId":"NCT00969644","phase":"NA","title":"The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons","status":"UNKNOWN","sponsor":"Herlev Hospital","startDate":"2009-09","conditions":["Interaction Between the GH/IGF-I System and the Immune-system"],"enrollment":12,"completionDate":"2010-03"},{"nctId":"NCT00476879","phase":"NA","title":"Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2006-08","conditions":["Metabolism","Fatty Liver"],"enrollment":10,"completionDate":"2008-06"},{"nctId":"NCT00143416","phase":"PHASE3","title":"Long Term Study With B2036-PEG","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-04","conditions":["Acromegaly"],"enrollment":16,"completionDate":"2007-07"},{"nctId":"NCT00151437","phase":"PHASE4","title":"Canadian Pegvisomant Compassionate Study In Acromegalic Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-11","conditions":["Acromegaly"],"enrollment":30,"completionDate":"2007-04"},{"nctId":"NCT00068029","phase":"PHASE4","title":"Pegvisomant And Sandostatin LAR Combination Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-10","conditions":["Acromegaly"],"enrollment":75,"completionDate":"2006-05"},{"nctId":"NCT00068042","phase":"PHASE4","title":"A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-04","conditions":["Acromegaly"],"enrollment":100,"completionDate":"2006-05"},{"nctId":"NCT00595140","phase":"PHASE4","title":"Acute Application of Pegvisomant and Octreotide in Acromegaly","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-01","conditions":["Acromegaly"],"enrollment":10,"completionDate":"2008-03"},{"nctId":"NCT00642720","phase":"PHASE4","title":"Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2006-10","conditions":["Quality of Life","Acromegaly"],"enrollment":20,"completionDate":"2007-07"},{"nctId":"NCT00017927","phase":"PHASE3","title":"A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome","status":"COMPLETED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2001-06","conditions":["McCune Albright Syndrome","Polyostotic Fibrous Dysplasia"],"enrollment":10,"completionDate":"2005-06"},{"nctId":"NCT00512473","phase":"NA","title":"Growth Hormone Signaling in Vivo in Humans","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2005-09","conditions":["Intracellular Signaling Peptides and Proteins"],"enrollment":8,"completionDate":"2006-04"},{"nctId":"NCT00468624","phase":"NA","title":"Effect of Pegvisomant on GH/IGF-I Relationship in GHD","status":"TERMINATED","sponsor":"The Christie NHS Foundation Trust","startDate":"2004-12","conditions":["Severe Adult Growth Hormone Deficiency"],"enrollment":0,"completionDate":"2005-07"}],"_emaApprovals":[{"date":"2002-11-13","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000148808","MMSL":"17174","NDDF":"009929","UNII":"N824AOU5XV","VUID":"4021390","VANDF":"4021390","INN_ID":"7941","RXNORM":"278739","UMLSCUI":"C0913469","chemblId":"CHEMBL1201515","ChEMBL_ID":"CHEMBL1201515","KEGG_DRUG":"D05394","DRUGBANK_ID":"DB00082","SNOMEDCT_US":"409201000","IUPHAR_LIGAND_ID":"7485","MESH_SUPPLEMENTAL_RECORD_UI":"C406545"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2003-","companyName":"Pharmacia And Upjohn","relationship":"Original Developer"}],"publicationCount":19,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"H01AX01","allCodes":["H01AX01"]},"biosimilarFilings":[],"originalDeveloper":"Pharmacia And Upjohn","recentPublications":[{"date":"2006","pmid":"30000555","title":"Pegvisomant.","journal":""},{"date":"2022","pmid":"36276070","title":"Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma.","journal":"Frontiers in oncology"},{"date":"2022 Sep 21","pmid":"35994522","title":"Moving Protein PEGylation from an Art to a Data Science.","journal":"Bioconjugate chemistry"},{"date":"2018 Jun","pmid":"29805678","title":"Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol.","journal":"Oncology letters"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small Molecule","firstApprovalDate":"2003","aiSummary":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:09.914644+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}